Calliditas Therapeutics AB CALT

NAS: CALT | ISIN: US13124Q1067 20/09/2024

40,00 USD (-0,40%)

(-0,40%) 20/09/2024

Grafiek Calliditas Therapeutics AB

Grafiek Calliditas Therapeutics AB

1 dag1d -0,40%
1 week1w 0,00%
1 maand1m 0,00%
3 maanden3m 3,09%
6 maanden6m 80,70%
1 jaar1j 138,36%
5 jaar5j 104,08%

Calliditas Therapeutics AB in het nieuws

Toon enkel gratis nieuws

5 juni 2024 · STOCKHOLDER INVESTIGATION: The M&A Class Action Firm Announces An Investigation of the Merger and its Tender Offer, Expiring July 18, 2024, for shares of Calliditas Therapeutics AB - CALT · Persbericht

12 maart 2024 · Everest Medicines' Partner Calliditas Therapeutics Announces U.S. FDA Grants an Additional Seven-Year Orphan Drug Exclusivity Period for Nefecon® · Persbericht

21 augustus 2023 · Everest Medicines Announces Partner Calliditas Therapeutics Receives FDA Priority Review for Full Approval of Nefecon® for the Treatment of IgA Nephropathy · Persbericht

18 augustus 2023 · Everest Medicines' Partner Calliditas Therapeutics Announces Full Results From NefIgArd Phase 3 Trial published in The Lancet · Persbericht

18 juli 2022 · Everest Medicines Announces European Commission Grants Approval of Kinpeygo® for Adults with Primary IgA Nephropathy to our Partner Calliditas Therapeutics · Persbericht

Profiel Calliditas Therapeutics AB

Fabricage van farmaceutische preparaten

Gezondheidstechnologie

CEO: Renee J. Aguiar-Lucander

Werknemers: 46

Mijn selecties

Je selectie is nog leeg.

Voeg nu effecten toe